Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00839007 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure
A Phase 2 study, sponsored by Nile Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT00839007: Completed Phase 2 study, sponsored by Nile Therapeutics.
NCT00839007 is a Phase 2 study that has completed, run by Nile Therapeutics. The registered enrollment target is 77 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00839007, a Phase 2 study, has completed, sponsored by Nile Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the safety and tolerability of IV administration of CD-NP and the dose relationship of CD-NP on improvement of clinical symptoms and renal function in ADHF patients.
Interventions
- DRUG CD-NP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
What the finished NCT00839007 record still lists
NCT00839007 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 1 intervention - of which CD-NP is the first listed.
NCT00839007 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00839007 about?
NCT00839007 is a clinical study titled "Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure". The primary objective of the study is to assess the safety and tolerability of IV administration of CD-NP and the dose relationship of CD-NP on improvement of clinical symptoms and renal function in ADHF patients.
What is the current status of trial NCT00839007?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2009-06. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00839007?
The interventions under investigation include: CD-NP (DRUG).
Who is sponsoring clinical trial NCT00839007?
This trial is sponsored by Nile Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00839007's enrollment target sits among peer trials
77 891st of 2000 higher than 1,108 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia